A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07517250
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Year - N/A
Healthy Volunteers
Not accepted

Study Details

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Key Dates

First listed
Apr 8, 2026
Start date
Mar 15, 2026
Status verified
Jun 2026
Primary completion
Dec 3, 2026
Completion
Dec 3, 2026

Study Design

Enrollment
160 participants (estimated)

Arms

  • Arm: FMF Cohort
    Patients diagnosed with FMF that received canakinumab for at least 6 months.
  • Arm: SJIA Cohort
    Patients diagnosed with SJIA that received canakinumab for at least 6 months.
  • Arm: AOSD Cohort
    Patients diagnosed with AOSD that received canakinumab for at least 6 months.

Primary Outcome Measure

Percentage of Patients With Clinically Inactive Disease Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents [ Time Frame: Up to 3 years ]

Central Contacts